Martini started helping people in 2004 after Hurricane Charley hit Florida. But more than 20 years later, what began as ...

MoonLake Immunotherapeutics is for sale? This sounds like a cry for help, STAT's Adam Feuerstein writes.

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times ...

MoonLake’s stock rocketed 20% after reports claimed Merck made a $3 billion acquisition offer to boost its drug pipeline.

Stocks closed higher on Tuesday as the Nasdaq Composite finished the day higher for the year even as uncertainty over global ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Merck recently made a nonbinding offer to acquire Swiss biotech firm MoonLake for over $3 billion, seeking to boost its drug ...

Short interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) decreased during the last reporting period, falling from 6.63M to 6.10M. This put 21.56% of the company's publicly available shares short.

Headlines UK must spend 68 billion pounds to modernise military, defence review suggests EU restricts Chinese medical devices in new trade dispute Saudi Aramco raises $5 billion in bond sale as it ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...